Pharma BD Deal Intelligence

Novartis AG / Agenus Inc.

2017 · Licensing/Option · $2.6B · Complete

Outcome Score

32

Underwhelmed — fell short of the thesis.

Novartis licensed Agenus' anti-PD-1 antibody balstilimab (AGEN2034) for global development in immuno-oncology combinations.

Key facts

Announced Nov 28, 2017
Deal value $2.6B
Deal type Licensing/Option
Therapeutic area Oncology
Indications Cervical cancer, Solid tumors
Key assets balstilimab (AGEN2034)
Mechanism Anti-PD-1 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals